RMP-7. Potential as an adjuvant to the drug treatment of brain tumours

CNS Drugs

Volumn 7, Issue 4, 1997, Pages 257-263

  Boddy, Alan V ^a   Thomas, Huw D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRADYKININ; CARBOPLATIN; LOBRADIMIL; NONAPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; DRUG TOLERANCE; DRUG UPTAKE; ERYTHEMA; FLUSHING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SURVIVAL; TACHYCARDIA; VASODILATATION;

EID: 0030973794     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199707040-00001     Document Type: Review

References (57)

1. Blasberg RG, Groothuis DR. Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Semin Oncol 1986; 13 (1): 70-82
2. Shapiro WR, Shapiro JR. Principles of brain tumor chemotherapy. Semin Oncol 1986; 13 (1): 56-69
3. Greig NH. Optimizing drug delivery to brain tumors. Cancer Treat Rev 1987; 14: 1-28
4. Stewart DJ. A critique of the role of the blood-brain-barrier, in the chemotherapy of human brain-tumors. J Neurooncol 1994; 20 (2): 121-39
5. Nakagawa H, Fujita T, Kubo S, et al. Difference in CDDP penetration into CSF between selective intraarterial chemotherapy in patients with malignant glioma and intravenous or intracarotid administration in patients with metastatic brain tumor. Cancer Chemother Pharmacol 1996; 37: 317-26
6. Stewart D, Molepo J, Green R, et al. Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin. Br J Cancer 1995; 71: 598-604
7. Donelli MG, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol 1992; 30: 251-60
8. Gumerlock MK, Belshe BD, Madsen R, et al. Osmotic blood-brain-barrier disruption and chemotherapy in the treatment of high-grade malignant glioma - patient series and literature-review. J Neurooncol 1992; 12 (1): 33-46
9. Williams PC, Henner WD, Roman-Goldstein S, et al. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumour barrier in the treatment of intracranial neoplasms. Neurosurgery 1995; 37 (1): 17-28
10. Markowsky SJ, Zimmerman CL, Tholl D, et al. Methotrexate disposition following disruption of the blood-brain-barrier. Ther Drug Monit 1991; 13 (1): 24-31
11. Madajewicz S, Chowhan N, Iliya A, et al. Intracarotid chemotherapy with etoposide and cisplatin for malignant brain tumors. Cancer 1991; 67 (11): 2844-9
12. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980; 32 (1): 1-46
13. Butt AM. Effect of inflammatory agents on electrical resistance across the blood-brain barrier in pial microvessels of anaesthetized rats. Brain Res 1995; 696: 145-50
14. Olesen SP, Crone C. Substances that rapidly augment ionic conductance of endothelium in cerebral venules. Acta Physiol Scand 1986; 127: 233-41
15. Raymond JJ, Robertson DM, Dinsdale HB. Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier. Can J Neurol Sci 1986; 13: 214-20
16. Inamura T, Nomura T, Ikezaki K, et al. Intracarotid histamine infusion increases blood tumour permeability in RG2 glioma. Neurolog Res 1994; 16 (2): 125-8
17. Black KL, King WA, Ikezaki K. Selective opening of the blood-tumor barrier by intracarotid infusion of leukotriene C4. J Neurosurg 1990; 72: 912-6
18. Wahl M, Unterberg A, Baethmann A, et al. Mediators of blood-brain barrier dysfunction and formation of vasogenic brain edema. J Cereb Blood Flow Metab 1988; 8: 621-34
19. Unterberg A, Wahl M, Baethmann A. Effects of bradykinin on permeability and diameter of pial vessels in vivo. J Cereb Blood Flow Metab 1984; 4: 574-85
20. Janigro D, West GA, Nguyen TS, et al. Regulation of blood-brain-barrier endothelial-cells by nitric-oxide. Circ Res 1994; 75 (3): 528-38
21. Nakano S, Matsukado K, Black KL. Increased brain tumor microvessel permeability alter intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res 1996; 56: 4027-31
22. Nomura T, Inamura T, Black KL. Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res 1994; 659 (1-2): 62-6
23. Inamura T, Black KL. Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 1994; 14: 862-70
24. Koga H, Inamura T, Ikezaki K, et al. Increased delivery of a new cisplatin analog (254-S) in a rat-brain tumor by an intracarotid infusion of bradykinin. Neurolog Res 1996; 18 (3): 244-7
25. 2-kinin receptors in the renal tubular and hemodynamic response to bradykinin. Am J Physiol 1992; 262 (31): R72-6
26. Buggs JF, Stokke ES, Kiil F. Effects of bradykinin and papaverine on renal autoregulation and renin release in the anaesthetized dog. Acta Physiol Scand 1991; 143 (4): 431-7
27. Fenoy FJ, Roman RJ. Effect of kinin receptor antagonists on renal hemodynamic and natriuretic responses to volume expansion. Am J Physiol 1992; 263 (32): R1136-40
28. Ader JL, Praddaude F, van Tran T, et al. Direct effects of bradykinin on glomerular filtration and proximal tubule reabsorption in rat kidney. Agents Actions Suppl 1992; 38 (3): 128-33
29. Straub JA, Akiyama A, Parmar P. In vitro plasma metabolism of RMP-7. Pharm Res 1994; 11: 1673-6
30. Doctrow SR, Abelleira SM, Curry LA, et al. The bradykinin analog, RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells. J Pharmacol Exp Ther 1994; 271 (1): 229-37
31. Bartus RT, Elliott P, Hayward N, et al. Permeability of the BBB by the bradykinin agonist, RMP-7: evidence for a sensitive, auto-regulated, receptor-mediated system. Immunopharmacology 1996; 33: 270-8
32. Straub JA, Akiyama A, Parmar P, et al. Chemical pathways of degradation of the bradykinin analog, RMP-7. Pharm Res 1995; 12 (2): 305-8
33. Jordan T, Walus L, Velickovic A, et al. A competitive chemiluminescent ELISA for the determination of RMP-7 in human blood. J Pharm Biomed Anal 1996; 14: 1653-62
34. Sanovich E, Bartus RT, Friden PM, et al. Pathway across blood-brain barrier opened by the bradykinin agonist RMP-7. Brain Res 1995; 705: 125-35
35. Matsukado K, Inamura T, Nakano S, et al. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 1996; 39 (1): 125-34
36. Inamura T, Nomura T, Bartus RT, et al. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg 1994; 81: 752-8
37. Dean RL, Elliott PJ, Nagle TL, et al. RMP-7 increases uptake of carboplatin into rat gliomas: comparison of three cell lines [abstract no. 2063]. Proceedings of the American Association for Cancer Research; Washington, 1996 Apr 20-24; 37: 303
38. Elliott PJ, Hayward NJ, Dean RL, et al. Intravenous RMP-7 selectively increases uptake of carboplatin into rat-brain tumors. Cancer Res 1996; 56 (17): 3998-4005
39. Elliot PJ, Hayward NJ, Huff MR, et al. Unlocking the blood brain-barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol 1996; 141: 214-24
40. Elliott PJ, Hayward NJ, Dean RL, et al. Dissociation of blood-brain-barrier permeability and the hypotensive effects of the bradykinin B2 agonist, RMP-7. Immunopharmacology 1996; 33 (1-3): 205-8
41. Grous JJ, Elliott PJ, Nayward NJ, et al. Clinical development of RMP-7, a bradykinin analogue to enhance the delivery of chemotherapeutics to malignant glioma [abstract], 8th International Conference on the Adjuvant Therapy of Cancer: 1996 Mar; Scottsdale (AZ)
42. Alavi A, Graney WFC, Buchpiguel C, et al. The effects of RMP-7 on the blood-brain barrier (BBB) permeability as determined by imaging techniques [abstract]. Annual Meeting of the Society of Nuclear Medicine: 1994 Jun; Orlando
43. Ford JM, Miles KA, Hayball MP, et al. A simplified technique for measurement of blood-brain barrier permeability using computed tomography: preliminary results of the effect of RMP-7. In: Faulkner K, Carey B, Crellin A, et al., editors. Quantitative Imaging in Oncology. Proceedings of the 19th L.H. Gray Conference. London: British Institute of Radiology, 1996: 1-3
44. Warnke PC, Weyerbrock A, Ostertag CB. Effect of the synthetic bradykinin RMP-7 on capillary permeability in glioblastoma multiforme [abstract]. Central Blatt fur Neurochirurgie 1996; Suppl.: 16
45. Doz R, Berens ME, Dougherty DV, et al. Comparison of the cytotoxic activities of cisplatin and carboplatin against glioma cell lines at pharmacologically relevant drug exposures. J Neurooncol 1991; 11 (1): 27-35
46. Dodion P, Sanders C, Georges P, et al. In vitro chemosensitivity of brain tumors to cisplatin and its analogues, iproplatin and carboplatin. Cancer Chemother Pharmacol 1988; 22: 80-2
47. Riccardi R, Riccardi A, Di Rocco C, et al. Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors. Cancer Chemother Pharmacol 1992; 30: 21-4
48. Brunner V, Houyau P, Chatelut E, et al. Cerebrospinal fluid concentrations of carboplatin in a patient without blood-brain barrier disruption. Cancer Chemother Pharmacol 1995; 35 (4): 352-3
49. Warnick RE, Prados MD, Mack EE, et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol 1994; 19 (1): 69-74
50. Twelves CJ, Ash CM, Miles DW, et al. Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma. Cancer Chemother Pharmacol 1991; 27: 481-3
51. Yung WKA, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991; 9 (5): 860-4
52. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7 (11): 1748-56
53. Bleehen NM, Ford JM, Miles KA, et al. A phase I dose rising study of RMP-7 and carboplatin in patients with recurrent malignant glioma [abstract]. J Neurooncol 1996 Nov; 30 (2): 107
54. Siddik ZH, Grous JJ, Chang S, et al. Pharmacokinetics of carboplatin and RMP-7 in patients with recurrent malignant glioma [abstract no. 1513]. Proceedings of the American Society for Clinical Oncology: 1996 May 18-21; Philadelphia; 15: 477
55. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87: 573-80
56. Thomas HD, Newell DR, Calvert AH, et al. Clinical studies with the novel bradykinin analogue RMP-7 and carboplatin in patients with glioma. Br J Cancer 1996; 73 Suppl. 26: 15
57. FDC Reports - Pink Sheet 1997; Jan 20: 19